Cargando…
Chronic ischaemic heart disease and rivaroxaban: which patients derive the greatest benefit?
Patients with established cardiovascular (CV) disease may suffer further CV events, despite receiving optimal medical treatment. Although platelet inhibition plays a central role in the prevention of new events, the use of anticoagulant therapies to reduce events in atheromatous disease has, until r...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Oxford University Press
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7673606/ https://www.ncbi.nlm.nih.gov/pubmed/33239976 http://dx.doi.org/10.1093/eurheartj/suaa128 |